Antitumor agents 288: Design, synthesis, SAR, and biological studies of novel heteroatom-incorporated antofine and cryptopleurine analogues as potent and selective antitumor agents

Xiaoming Yang, Qian Shi, Shuenn Chen Yang, Chi Yuan Chen, Sung Liang Yu, Kenneth F. Bastow, Susan L. Morris-Natschke, Pei Chi Wu, Chin Yu Lai, Tian Shung Wu, Shiow Lin Pan, Che Ming Teng, Jau Chen Lin, Pan Chyr Yang, Kuo Hsiung Lee

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Novel heteroatom-incorporated antofine and cryptopleurine analogues were designed, synthesized, and tested against a panel of five cancer cell lines. Two new S-13-oxo analogues (11 and 16) exhibited potent cell growth inhibition in vitro (GI 50: 9 nM and 20 nM). Interestingly, both compounds displayed improved selectivity among different cancer cell lines, in contrast to the natural products antofine and cryptopleurine. Mechanism of action (MOA) studies suggested that R-antofine promotes dysregulation of DNA replication during early S phase, while no similar effects were observed for 11 and 15 on corresponding replication initiation complexes. Compound 11 also showed greatly reduced cytotoxicity against normal cells and moderate antitumor activity against HT-29 human colorectal adenocarcinoma xenograft in mice without overt toxicity.

Original languageEnglish
Pages (from-to)5097-5107
Number of pages11
JournalJournal of Medicinal Chemistry
Volume54
Issue number14
DOIs
Publication statusPublished - Jul 28 2011
Externally publishedYes

Fingerprint

Antineoplastic Agents
5-chloro-3-tert-butyl-2'-chloro-4'-nitrosalicylanilide
Cell Line
Biological Products
DNA Replication
S Phase
Heterografts
Neoplasms
Adenocarcinoma
Growth
cryptopleurine
antofine
In Vitro Techniques

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery

Cite this

Antitumor agents 288 : Design, synthesis, SAR, and biological studies of novel heteroatom-incorporated antofine and cryptopleurine analogues as potent and selective antitumor agents. / Yang, Xiaoming; Shi, Qian; Yang, Shuenn Chen; Chen, Chi Yuan; Yu, Sung Liang; Bastow, Kenneth F.; Morris-Natschke, Susan L.; Wu, Pei Chi; Lai, Chin Yu; Wu, Tian Shung; Pan, Shiow Lin; Teng, Che Ming; Lin, Jau Chen; Yang, Pan Chyr; Lee, Kuo Hsiung.

In: Journal of Medicinal Chemistry, Vol. 54, No. 14, 28.07.2011, p. 5097-5107.

Research output: Contribution to journalArticle

Yang, X, Shi, Q, Yang, SC, Chen, CY, Yu, SL, Bastow, KF, Morris-Natschke, SL, Wu, PC, Lai, CY, Wu, TS, Pan, SL, Teng, CM, Lin, JC, Yang, PC & Lee, KH 2011, 'Antitumor agents 288: Design, synthesis, SAR, and biological studies of novel heteroatom-incorporated antofine and cryptopleurine analogues as potent and selective antitumor agents', Journal of Medicinal Chemistry, vol. 54, no. 14, pp. 5097-5107. https://doi.org/10.1021/jm200330s
Yang, Xiaoming ; Shi, Qian ; Yang, Shuenn Chen ; Chen, Chi Yuan ; Yu, Sung Liang ; Bastow, Kenneth F. ; Morris-Natschke, Susan L. ; Wu, Pei Chi ; Lai, Chin Yu ; Wu, Tian Shung ; Pan, Shiow Lin ; Teng, Che Ming ; Lin, Jau Chen ; Yang, Pan Chyr ; Lee, Kuo Hsiung. / Antitumor agents 288 : Design, synthesis, SAR, and biological studies of novel heteroatom-incorporated antofine and cryptopleurine analogues as potent and selective antitumor agents. In: Journal of Medicinal Chemistry. 2011 ; Vol. 54, No. 14. pp. 5097-5107.
@article{2201565cf88c4e738263555d81c1f974,
title = "Antitumor agents 288: Design, synthesis, SAR, and biological studies of novel heteroatom-incorporated antofine and cryptopleurine analogues as potent and selective antitumor agents",
abstract = "Novel heteroatom-incorporated antofine and cryptopleurine analogues were designed, synthesized, and tested against a panel of five cancer cell lines. Two new S-13-oxo analogues (11 and 16) exhibited potent cell growth inhibition in vitro (GI 50: 9 nM and 20 nM). Interestingly, both compounds displayed improved selectivity among different cancer cell lines, in contrast to the natural products antofine and cryptopleurine. Mechanism of action (MOA) studies suggested that R-antofine promotes dysregulation of DNA replication during early S phase, while no similar effects were observed for 11 and 15 on corresponding replication initiation complexes. Compound 11 also showed greatly reduced cytotoxicity against normal cells and moderate antitumor activity against HT-29 human colorectal adenocarcinoma xenograft in mice without overt toxicity.",
author = "Xiaoming Yang and Qian Shi and Yang, {Shuenn Chen} and Chen, {Chi Yuan} and Yu, {Sung Liang} and Bastow, {Kenneth F.} and Morris-Natschke, {Susan L.} and Wu, {Pei Chi} and Lai, {Chin Yu} and Wu, {Tian Shung} and Pan, {Shiow Lin} and Teng, {Che Ming} and Lin, {Jau Chen} and Yang, {Pan Chyr} and Lee, {Kuo Hsiung}",
year = "2011",
month = "7",
day = "28",
doi = "10.1021/jm200330s",
language = "English",
volume = "54",
pages = "5097--5107",
journal = "Journal of Medicinal Chemistry",
issn = "0022-2623",
publisher = "American Chemical Society",
number = "14",

}

TY - JOUR

T1 - Antitumor agents 288

T2 - Design, synthesis, SAR, and biological studies of novel heteroatom-incorporated antofine and cryptopleurine analogues as potent and selective antitumor agents

AU - Yang, Xiaoming

AU - Shi, Qian

AU - Yang, Shuenn Chen

AU - Chen, Chi Yuan

AU - Yu, Sung Liang

AU - Bastow, Kenneth F.

AU - Morris-Natschke, Susan L.

AU - Wu, Pei Chi

AU - Lai, Chin Yu

AU - Wu, Tian Shung

AU - Pan, Shiow Lin

AU - Teng, Che Ming

AU - Lin, Jau Chen

AU - Yang, Pan Chyr

AU - Lee, Kuo Hsiung

PY - 2011/7/28

Y1 - 2011/7/28

N2 - Novel heteroatom-incorporated antofine and cryptopleurine analogues were designed, synthesized, and tested against a panel of five cancer cell lines. Two new S-13-oxo analogues (11 and 16) exhibited potent cell growth inhibition in vitro (GI 50: 9 nM and 20 nM). Interestingly, both compounds displayed improved selectivity among different cancer cell lines, in contrast to the natural products antofine and cryptopleurine. Mechanism of action (MOA) studies suggested that R-antofine promotes dysregulation of DNA replication during early S phase, while no similar effects were observed for 11 and 15 on corresponding replication initiation complexes. Compound 11 also showed greatly reduced cytotoxicity against normal cells and moderate antitumor activity against HT-29 human colorectal adenocarcinoma xenograft in mice without overt toxicity.

AB - Novel heteroatom-incorporated antofine and cryptopleurine analogues were designed, synthesized, and tested against a panel of five cancer cell lines. Two new S-13-oxo analogues (11 and 16) exhibited potent cell growth inhibition in vitro (GI 50: 9 nM and 20 nM). Interestingly, both compounds displayed improved selectivity among different cancer cell lines, in contrast to the natural products antofine and cryptopleurine. Mechanism of action (MOA) studies suggested that R-antofine promotes dysregulation of DNA replication during early S phase, while no similar effects were observed for 11 and 15 on corresponding replication initiation complexes. Compound 11 also showed greatly reduced cytotoxicity against normal cells and moderate antitumor activity against HT-29 human colorectal adenocarcinoma xenograft in mice without overt toxicity.

UR - http://www.scopus.com/inward/record.url?scp=79960625636&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960625636&partnerID=8YFLogxK

U2 - 10.1021/jm200330s

DO - 10.1021/jm200330s

M3 - Article

C2 - 21668000

AN - SCOPUS:79960625636

VL - 54

SP - 5097

EP - 5107

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

IS - 14

ER -